|
|
| Where Formulation Expertise Connects | As pipelines grow more complex and timelines become more ambitious, companies increasingly rely on strong external partners to advance their drug products efficiently and with reduced risk. This is where integrated expertise in formulation development, analytical characterization, and CMC strategy becomes a key enabler for successful partnerships. The BIO International Convention in San Diego is one of the leading global partnering events for the biotech and pharmaceutical industry, bringing together innovators, decision-makers, and service providers to build meaningful collaborations. Learn more. |
|
|
|
|
|
| Digital Innovation And Sustainability Are Redefining Biomanufacturing | White Paper | By Dr. Harald Bradl and Dr. Fabian Vogt, Boehringer Ingelheim Biopharmaceuticals | Next Generation Manufacturing (NGM) integrates advanced process design, digital innovation, and strategic facility planning to facilitate agile, efficient, and sustainable biopharmaceutical production. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Biopharma outsourcing is impacted by geopolitics and government policy. COVID. BIOSECURE Act. Trump’s tariffs. China chicanery. Europe’s repositioning. South Korea’s rise. India’s widening role. And now we seem to be crossing the Rubicon to FDA regulatory discontinuity impacting our supply chains. How is the FDA currently impacting development and manufacturing outsourcing? | |
|
|
Mapping Candel Therapeutics' Sprint To The BLA Finish Line | A conversation with Paul Peter Tak and Seshu Tyagarajan of Candel Therapeutics and Life Science Connect's Jon O'Connell | Leaders from the adenovirus/prodrug developer discuss the complex balancing act of preparing to scale up for commercial manufacturing without overextension. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
|
|
| Humanization Of High Affinity Therapeutic Antibodies | Poster | By Vydehi Kanneganti, Nicole Polewaczyk, Roger Wong, and Brian A. Zabel, Curia | Here, we present a hybridoma-based antibody discovery and humanization strategy for a T1P target, utilizing Penta Mice immunization to generate monoclonal antibodies. |
|
|
|
|
|
|
|
|
| Webinar: Cracking complexity: Learnings from 70+ bispecific antibody programs | Discover how early-stage biotech teams can reduce risk and accelerate bispecific antibody development in this webinar from Lonza. Drawing on insights from 70+ programs, Lonza experts explore key challenges across analytical development, downstream purification, and formulation, while sharing practical strategies to support IND readiness, avoid costly delays, and confidently advance complex biologics toward the clinic with greater speed and long-term success. Click here to learn more. |
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|